Brief: INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 Mindful Alzheimer's Trial
02/06/2026 13:05
BRIEF-INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 Mindful Alzheimer's Trial June 2 (Reuters) - INmune Bio Inc INMB.O:
INMUNE BIO REPORTS STATISTICALLY SIGNIFICANT TREATMENT EFFECT ON ADVANCED WHITE MATTER MRI BIOMARKER IN PHASE 2 MINDFUL ALZHEIMER'S TRIAL
INMUNE BIO - XPRO1595 SHOWS SIGNIFICANT TREATMENT EFFECT IN FULL MITT POPULATION
INMUNE BIO - XPRO1595 EFFICACY STRENGTHENED IN BIOMARKER-ENRICHED PATIENTS WITH ELEVATED INFLAMMATION
Source text: ID:nGNEcb0Cpw
Further company coverage: INMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview